Vedanta announces millions in funding and new study

Vedanta announces millions in funding and new study

Vedanta Biosciences, a clinical-stage company, has raised $106.5million to support its lead candidate VE303 that aims to stop recurrent Clostridioides difficile​ infection (CDI). The company has also announced a phase 2 study of VE202 for ulcerative colitis. It says...